Molecular Biomarkers in the Cerebrospinal Fluid in Multiple Sclerosis

被引：0
作者：
Shedko E.D. [1 ]
Tyumentseva M.A. [1 ]
机构：
[1] Central Research Institute of Epidemiology, Russian Federal Service for Surveillance of Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor), Moscow
来源：
Neuroscience and Behavioral Physiology | 2020年 / 50卷 / 5期
关键词：
autoimmune diseases; biomarkers; cerebrospinal fluid; multiple sclerosis;
D O I：
10.1007/s11055-020-00932-z
中图分类号：
学科分类号：
摘要：
Multiple sclerosis (MS) is a chronic autoimmune disease affecting the spinal cord and brain. Detection of the disease at its initial stages is a difficult task as the causes and mechanisms of the manifestations of the disease remain unclear. Diagnosis of MS is a complex process. Studies of the molecular mechanisms of the disease and the search for biomarkers are among the key directions in the diagnosis of the disease. This review addresses potential biomarkers for multiple sclerosis detected in the cerebrospinal fluid. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.
引用
收藏
页码：527 / 533
页数：6
相关论文
共 80 条
  • [41] Roessmann U., Velasco M.E., Sindely S.D., Gambetti P., Glial fibrillary acidic protein (GFAP) in ependymal cells during development. An immunocytochemical study, Brain Res., 200, pp. 13-21, (1980)
  • [42] Martinez M.A., Olsson B., Bau L., Et al., Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis, Mult. Scler., 21, 5, pp. 550-561, (2015)
  • [43] Axelsson M., Malmestrom C., Nilsson S., Et al., Glial fi brillary acidic protein: a potential biomarker for progression in multiple sclerosis, J. Neurol., 258, 5, pp. 882-888, (2011)
  • [44] Semra Y.K., Seidi O.A., Sharief M.K., Heightened intrathecal release of axonal cytoskeletal proteins in multiple sclerosis is associated with progressive disease and clinical disability, J. Neuroimmunol., 122, 1-2, pp. 132-139, (2002)
  • [45] Madeddu R., Farace C., Tolu P., Et al., Cytoskeletal proteins in the cerebrospinal fluid as biomarker of multiple sclerosis, Neurol. Sci., 34, 2, pp. 181-186, (2013)
  • [46] Cyster J.G., Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs, Annu. Rev. Immunol., 23, pp. 127-159, (2005)
  • [47] Okada T., Cyster J.G., B cell migration and interactions in the early phase of antibody responses, Curr. Opin. Immunol., 18, pp. 278-285, (2006)
  • [48] Khademi M., Kockum I., Andersson M.L., Et al., Cerebrospinal fluid CXCL13 in multiple sclerosis: A suggestive prognostic marker for the disease course, Mult. Scler., 17, pp. 335-343, (2011)
  • [49] Brettschneider J., Czerwoniak A., Senel M., Et al., The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS), PLoS One, 5, 8, (2010)
  • [50] Mashayekhi F., Salehi Z., Jamalzadeh H.R., Quantitative analysis of cerebrospinal fluid brain derived neurotrophic factor in the patients with multiple sclerosis, Acta Medica (Hradec Kralove), 55, 2, pp. 83-86, (2012)
12345678